Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Choosing the right beta-blocker. A guide to selection

J R Hampton1

  • 1Queen's Medical Centre, University Hospital, Nottingham, England.

Drugs
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The end of clinical freedom.

International journal of epidemiology·2011
Same author

Effect of aggregating agents on the electrophoretic mobility of human platelets.

British medical journal·2010
Same author

Microdisplacement printing.

Nano letters·2005
Same author

Thermally enhanced neutralization in hyperthermal energy ion scattering.

Physical review letters·2003
Same author

Size isn't everything.

Statistics in medicine·2002
Same author

Pathological features of witnessed out-of-hospital cardiac arrest presenting with ventricular fibrillation.

Resuscitation·2001
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Beta-blockers are established treatments for high blood pressure and heart attack recovery. Current research explores their role in heart failure, with large trials guiding clinical practice for optimal beta-blocker selection.

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Beta-blockers have been used for three decades, with established roles in hypertension, myocardial infarction secondary prevention, and arrhythmias.
  • The efficacy of beta-blockers in heart failure is under ongoing investigation.
  • A new generation of beta-blockers with vasodilating properties is emerging, but lacks extensive clinical trial data.

Purpose of the Study:

  • To review the evidence supporting the use of beta-blockers in major cardiovascular conditions.
  • To assess the current understanding of beta-blocker efficacy based on large-scale clinical trials.
  • To highlight areas of ongoing research, particularly the role of beta-blockers in heart failure.

Main Methods:

  • Review of major clinical trials in hypertension, myocardial infarction, arrhythmias, and heart failure.

Related Experiment Videos

  • Analysis of evidence for the use of specific beta-blockers in defined patient populations.
  • Evaluation of comparative studies and the limitations of small trials or meta-analyses.

    • Main Results:

    • Beta-blockers show no significant advantage over other agents for hypertension.
    • Late beta-blocker use reduces mortality post-myocardial infarction; early use efficacy is less clear.
    • Beta-blockers are effective in preventing sudden death and show potential in heart failure research, though comparative data is limited.

    Conclusions:

    • Clinical practice should be guided by large-scale trial results for individual beta-blockers.
    • Propranolol and atenolol are well-studied for hypertension; timolol for post-myocardial infarction; sotalol for arrhythmias.
    • The optimal beta-blocker for heart failure requires further investigation through large clinical trials.